News
Panelists discuss how the PODIUM-303 study demonstrated improved progression-free survival (9.3 vs 7.4 months) and response rates (56% vs 44%) when adding retifanlimab to carboplatin-paclitaxel in ...
15h
MedPage Today on MSNCOVID Boosters Protect Against Severe Disease in Cancer PatientsCOVID-19 booster shots appeared to protect against severe disease among patients with cancer, according to a large retrospective cohort study. With a monovalent booster, the vaccine effectiveness to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results